Where should you get cancer treatment? The honest answer is: it depends.

A research-backed guide to choosing a cancer center, oncologist, or care team — and why the right answer looks different for every patient.

One of the questions I get asked most often is some version of this: “Should I go to MD Anderson? Should I travel to get treated at a top cancer center? Or is my local cancer facility good enough?”

I understand why this feels urgent. You’ve just been diagnosed. You want the best possible chance. And you’ve probably already Googled rankings, read about famous cancer centers, and wondered whether where you go for treatment will determine whether you survive.

The honest answer is that where you get treated genuinely matters — but not always in the way patients expect. The “right” answer depends heavily on what kind of cancer you have, how complex your case is, what resources you have access to, and what trade-offs you’re willing to make. Let me walk you through how to think about this clearly.

The rankings exist — and they matter, with caveats

Yes, there are published rankings of the world’s best oncology hospitals. Newsweek’s World’s Best Specialized Hospitals 2026 list — compiled in partnership with Statista using surveys of tens of thousands of healthcare professionals, accreditation data, and patient outcome measures — ranked Memorial Sloan Kettering Cancer Center (MSK) in New York first globally for oncology, followed by MD Anderson Cancer Center in Houston. Johns Hopkins, Mayo Clinic, and a handful of other U.S. institutions also made the top 10. U.S. News & World Report’s domestic rankings, which lean more heavily on risk-adjusted patient outcomes, placed MD Anderson first in the nation for the 11th consecutive year, with MSK second.

These institutions are genuinely exceptional. The research that comes out of them shapes global treatment standards. Their multidisciplinary teams — where surgeons, medical oncologists, radiation oncologists, pathologists, and radiologists meet weekly in tumor boards to discuss individual cases — represent a level of coordinated expertise that is hard to replicate. They see enormous volumes of patients, which matters because in oncology, practice really does make a measurable difference.

But here’s what the rankings don’t tell you: they are institutional reputations, not guarantees about your individual outcome. And they say nothing at all about whether traveling to New York or Houston is the right decision for you specifically.

What the research actually says about where you’re treated

There is real scientific evidence that where you receive cancer treatment affects your outcomes — particularly for certain cancer types and particularly for surgically complex cases. Here’s what the data shows:

• For complex or rare cancers, volume and specialization matter enormously. A landmark study published in JAMA Oncology found that patients treated at the 11 freestanding specialized cancer hospitals in the U.S. had a five-year survival rate of 53%, compared to 44% at community hospitals. A separate population-based study of nearly 70,000 patients in Los Angeles County found that those treated at NCI-designated Comprehensive Cancer Centers had superior survival outcomes across multiple cancer types compared to those treated in community settings.

• Surgical complexity is where the gap is widest. Research has shown mortality after esophagectomy and pancreatectomy can be two to three times higher at low-volume hospitals compared to high-volume centers. For head and neck cancers related to HPV, a 2024 Johns Hopkins study published in the Journal of the National Cancer Institute found that patients treated at community centers had survival rates roughly 6 percentage points lower than those at academic centers — and were less likely to receive guideline-recommended care.

• For common cancers at standard stages, the gap may be smaller than you think. A Medscape analysis noted that for common cancers when controlling for case mix, the survival difference between academic and community practice may not be clinically meaningful. Only 8–10% of cancer patients are currently treated at large academic centers — if everyone with a common, early-stage cancer traveled to major centers, it would overwhelm those institutions without necessarily improving outcomes for most patients.

• Community practices are not created equal. The best community practices are genuinely excellent. Some run phase 2 and phase 3 clinical trials that rival what academic centers offer. Large national networks like US Oncology allow community oncologists to subspecialize and share best practices. The ASCO Post has reported research suggesting community practices can outperform academic centers on personalized care, accessibility, and cost-effectiveness. The key question isn’t “academic vs. community” — it’s how well any given practice is resourced, how specialized its physicians are, and what volume of your specific cancer type they see.

The honest problem with community oncology

Here is something I think patients deserve to hear plainly: not all community oncology practices are equal, and some are asking individual oncologists to do something that is genuinely difficult — treat too many different cancer types with too little subspecialty support.

A solo or two-physician practice where one doctor sees lung cancer, colon cancer, breast cancer, leukemia, and rare sarcomas on the same day cannot maintain the same depth of subspecialty expertise as a physician who restricts their practice to one cancer type. An oncologist at a major academic center may see one rare leukemia subtype dozens of times a year; a community generalist may see it once or twice. The difference between treating a rare cancer a few times a year versus dozens of times is substantial — and no amount of dedication fully closes that gap.

This isn’t a criticism of community oncologists — many are excellent clinicians — but it is a structural reality that patients should understand when evaluating their options.

A framework for thinking through your own decision

Rather than defaulting to “go to the best-ranked center” or “stay local,” work through these questions:

Is your cancer rare or complex?

Rare cancers, aggressive subtypes, and cancers requiring complex surgery are where the evidence most clearly favors a high-volume specialized center. If you have a sarcoma, a rare blood cancer, a complex GI malignancy, or a head and neck cancer, seeking care at — or at least a consultation from — an NCI-designated Comprehensive Cancer Center is well-supported by the research.

Does your local practice subspecialize in your cancer type?

Ask directly: how many patients with my exact diagnosis do you treat per year? Do you have a dedicated disease team for my cancer type? Is there a weekly tumor board that reviews cases like mine? These questions reveal whether you’re receiving subspecialty care or generalist oncology.

Are there clinical trials you may be eligible for?

Approximately 85% of cancer patients are treated in community settings, but most clinical trials are run at academic and NCI-designated centers. If your cancer type has active trials that could benefit you, access to a major center — even just for initial evaluation — may open doors that community care cannot.

What are the real costs of traveling for care?

Travel adds financial cost, physical strain, and distance from your support network. For many cancers — particularly those requiring frequent treatment cycles over months — receiving standard-of-care chemotherapy at a high-quality local practice while having your case reviewed at a major center is a reasonable hybrid model. You don’t have to choose one or the other entirely.

Can you get a second opinion even if you stay local?

Many major cancer centers now offer remote second-opinion consultations where they review your pathology, imaging, and records without requiring you to travel. This is one of the most underutilized options in cancer care. It costs relatively little, takes a few weeks, and can confirm your treatment plan — or change it entirely.

Questions to ask any oncologist or cancer center

These questions apply whether you’re evaluating a community practice, an academic center, or a world-ranked institution:

For the oncologist:

• How many patients with my specific cancer type and stage do you treat per year?

• Do you subspecialize in this cancer, or do you treat multiple cancer types?

• Will my case be reviewed by a multidisciplinary tumor board?

• Are there clinical trials I should know about for my diagnosis?

• Would you recommend I get a second opinion at a major center? If not, why not?

For the cancer center or practice:

• Is this an NCI-designated Cancer Center, and if not, what accreditation does it hold?

• Do you have a disease-specific team for my cancer type?

• What supportive services are available — patient navigation, palliative care, nutrition, mental health?

• How do you handle care coordination if I need subspecialists outside this practice?

You don’t have to choose between “the best” and “what’s practical”

The most effective strategy for many patients is a hybrid one. Get your initial workup, pathology review, and treatment plan evaluated at the highest-expertise center you can access — even if it’s just a one-time second-opinion consultation. Then make a clear-eyed decision about where to receive ongoing treatment based on what your case actually requires.

If your cancer is common, your diagnosis is straightforward, your local oncologist subspecializes in your cancer type, and your practice has a tumor board and clinical trial access — staying local may be entirely appropriate. If your cancer is rare, complex, or your local practice is a small generalist group — getting at least one expert second opinion from a major center is not just reasonable, it’s something most oncologists would encourage.

The bottom line

Rankings tell you about institutional reputation. Volume data tells you about the relationship between experience and outcomes. Neither tells you exactly what the right choice is for your specific diagnosis. The right framework is: understand what your cancer requires, ask the right questions of any practice you’re evaluating, and don’t let geography alone make the decision for you. A second opinion costs far less than a wrong first treatment.

References & Disclaimer

This post is for educational purposes only and does not constitute medical advice. References include: Newsweek/Statista World’s Best Specialized Hospitals 2026; U.S. News & World Report Best Hospitals 2025–26; JAMA Oncology (MSK survival outcomes study); PMC/NIH population-based NCI-CCC study (Los Angeles County, n=69,579); Journal of the National Cancer Institute (Johns Hopkins HPV oropharyngeal cancer study, 2024); ASCO Post community oncology case study; Medscape academic-community oncology analysis. Always consult your oncologist or qualified healthcare provider before making care decisions.